Publisher: John Wiley & Sons Inc
E-ISSN: 1556-7567|17|4|1-7
ISSN: 1527-8395
Source: THE BROWN UNIVERSITY CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY UPDATE, Vol.17, Iss.4, 2015-04, pp. : 1-7
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Adolescents and children diagnosed with bipolar disorder (BP) have a significantly reduced quality of life, including greater risk of suicidal behavior. Rapid intervention is critical, but unfortunately pharmacological treatments are challenging, with antidepressants sometimes causing manic symptoms. While there are medications effective in treating mania, the depressive phase is more difficult to treat. Only three medications are approved by the Food and Drug Administration (FDA) for the acute treatment of bipolar depression in adults: quetiapine, lurasidone, and olanzapine/fluoxetine combination (OFC).
Related content
The effect of hospitalist discontinuity on adverse events
JOURNAL OF HOSPITAL MEDICINE, Vol. 10, Iss. 3, 2015-03 ,pp. :
Adverse Drug Events In High Risk Older Outpatients
JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 45, Iss. 8, 1997-08 ,pp. :
In reference to “The effect of hospitalist continuity on adverse events”
JOURNAL OF HOSPITAL MEDICINE, Vol. 10, Iss. 9, 2015-09 ,pp. :